Dose Escalation Completed for Rise Therapeutics’ R-3750 and R-2487 Clinical Trials

UF startup Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, announced that it has completed dose escalation enrollment stages for both its R-2487 and R-3750 clinical trials. Both studies will now initiate the planned dose expansion stages to enroll additional patients at fixed doses.